Literature DB >> 28547936

Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases.

Juliana da Fonseca Rezende E Mello1, Renan Augusto Gomes1, Drielli Gomes Vital-Fujii1, Glaucio Monteiro Ferreira1,2, Gustavo Henrique Goulart Trossini1,2.   

Abstract

Neglected diseases (NDs) affect large populations and almost whole continents, representing 12% of the global health burden. In contrast, the treatment available today is limited and sometimes ineffective. Under this scenery, the Fragment-Based Drug Discovery emerged as one of the most promising alternatives to the traditional methods of drug development. This method allows achieving new lead compounds with smaller size of fragment libraries. Even with the wide Fragment-Based Drug Discovery success resulting in new effective therapeutic agents against different diseases, until this moment few studies have been applied this approach for NDs area. In this article, we discuss the basic Fragment-Based Drug Discovery process, brief successful ideas of general applications and show a landscape of its use in NDs, encouraging the implementation of this strategy as an interesting way to optimize the development of new drugs to NDs.
© 2017 John Wiley & Sons A/S.

Keywords:  FBDD; drug design; fragment; hit; neglected diseases; screening

Mesh:

Substances:

Year:  2017        PMID: 28547936     DOI: 10.1111/cbdd.13030

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  6 in total

1.  Expanded DNA and RNA Trinucleotide Repeats in Myotonic Dystrophy Type 1 Select Their Own Multitarget, Sequence-Selective Inhibitors.

Authors:  Lauren D Hagler; Long M Luu; Marco Tonelli; JuYeon Lee; Samuel M Hayes; Sarah E Bonson; J Ignacio Vergara; Samuel E Butcher; Steven C Zimmerman
Journal:  Biochemistry       Date:  2020-09-10       Impact factor: 3.162

Review 2.  Fragment-based screening with natural products for novel anti-parasitic disease drug discovery.

Authors:  Miaomiao Liu; Ronald J Quinn
Journal:  Expert Opin Drug Discov       Date:  2019-09-12       Impact factor: 6.098

Review 3.  Combining structure and genomics to understand antimicrobial resistance.

Authors:  Tanushree Tunstall; Stephanie Portelli; Jody Phelan; Taane G Clark; David B Ascher; Nicholas Furnham
Journal:  Comput Struct Biotechnol J       Date:  2020-10-29       Impact factor: 7.271

4.  In Vitro Antileishmanial and Antitrypanosomal Activities of Plicataloside Isolated from the Leaf Latex of Aloe rugosifolia Gilbert & Sebsebe (Asphodelaceae).

Authors:  Gete Chemeda; Daniel Bisrat; Mariamawit Y Yeshak; Kaleab Asres
Journal:  Molecules       Date:  2022-02-18       Impact factor: 4.411

Review 5.  Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.

Authors:  José T Moreira-Filho; Arthur C Silva; Rafael F Dantas; Barbara F Gomes; Lauro R Souza Neto; Jose Brandao-Neto; Raymond J Owens; Nicholas Furnham; Bruno J Neves; Floriano P Silva-Junior; Carolina H Andrade
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

Review 6.  Innovation in neglected tropical disease drug discovery and development.

Authors:  Hong-Bo Weng; Hai-Xia Chen; Ming-Wei Wang
Journal:  Infect Dis Poverty       Date:  2018-06-18       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.